Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Company Deals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

Fineline Cube Mar 30, 2026
Company Deals

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Drug

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Fineline Cube Mar 30, 2026
Company Deals

ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital

Fineline Cube Jul 25, 2022

Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution,...

Company Deals

Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion

Fineline Cube Jul 25, 2022

Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make...

Company Drug

Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital

Fineline Cube Jul 25, 2022

Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...

Company Deals

Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech

Fineline Cube Jul 22, 2022

Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...

Company Deals

Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001

Fineline Cube Jul 22, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...

Company Deals

Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment

Fineline Cube Jul 22, 2022

Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and...

Company Deals

Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development

Fineline Cube Jul 22, 2022

Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...

Drug

Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study

Fineline Cube Jul 22, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...

Company Drug

Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC

Fineline Cube Jul 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...

Company Deals

Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang

Fineline Cube Jul 22, 2022

China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...

Company Drug

Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye

Fineline Cube Jul 22, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity

Fineline Cube Jul 22, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Drug

Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study

Fineline Cube Jul 22, 2022

China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National...

Drug

Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors

Fineline Cube Jul 22, 2022

The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...

Company Deals

Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base

Fineline Cube Jul 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...

Company Drug

Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE

Fineline Cube Jul 22, 2022

The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...

Company

Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics

Fineline Cube Jul 22, 2022

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...

Company Drug

InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone

Fineline Cube Jul 22, 2022

China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...

Company Deals

Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC

Fineline Cube Jul 21, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...

Company Deals

MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines

Fineline Cube Jul 21, 2022

MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...

Posts pagination

1 … 623 624 625 … 643

Recent updates

  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
  • AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data
  • Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine
  • Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Company Drug

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Company Medical Device

Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.